Development and improvement of anti-gout property from aqueous-methanol extract of morinda elliptica using central composite design
Xanthine oxidase (XO) is a key enzyme in hyperuricemia, catalyzing the oxidation of hypoxanthine to xanthine and then to uric acid. Excess serum accumulated with uric acid leads to a type of arthritis known as gout. In this study, development of process conditions for XO inhibitory activity from t...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Conference or Workshop Item |
| Language: | English |
| Published: |
2013
|
| Subjects: | |
| Online Access: | http://irep.iium.edu.my/33526/1/ICBIOE_2.pdf http://irep.iium.edu.my/33526/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Xanthine oxidase (XO) is a key enzyme in hyperuricemia, catalyzing the oxidation of hypoxanthine to
xanthine and then to uric acid. Excess serum accumulated with uric acid leads to a type of arthritis known as
gout. In this study, development of process conditions for XO inhibitory activity from the leaves of Morinda
elliptica was performed by using 70% methanol. Optimization of process parameters such as extraction
temperature (ºC), extraction time (h), agitation speed (rpm) and ratio of sample to solvent (1g/ml) at five
levels was carried out using central composite design (CCD) for the improvement of activity to treat gout.
The analysis of variance demonstrated that the model F-value of 18.31 showed the significance of the model
with R2 of 97.71%. The analysis revealed that the percentage of XO inhibitory activity was improved at 32
ºC, 30 h, 125 rpm and 1 g/15 ml of solvent. The optimized conditions were verified and the percentage of
XO inhibitory activity obtained was 88.93%. The results are encouraging to formulate food, nutraceutical or
pharmaceutical products incorporating natural xanthine oxidase inhibitor (XOI), an alternative to
irresponsive synthetic XOI. |
|---|